B. Riley analyst Yuan Zhi kept a Buy rating on Foghorn Therapeutics (FHTX) with a $10 price target following a transfer of coverage. Foghorn is a clinical-stage biotech company developing targeted oncology therapies that modulate the chromatin regulatory system, the analyst tells investors in a research note. The firm believes investors are ignoring FHD-909’s upside potential and anticipates sequential positive reactions following PRT7732’s and FHD-909’s clinical readouts in late 2025 and early 2026E, respectively.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Advances in Precision Therapeutics
- Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
- Foghorn Therapeutics Reports Q2 2025 Financial Results
- Foghorn Therapeutics management to meet virtually with B. Riley
- Foghorn Therapeutics Reports Q2 2025 Financial Update